Low-grade Glioma Clinical Trial
Official title:
A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. There will also be secondary and exploratory objectives listed in the detailed description below.
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. The secondary objectives are to: 1. Determine 12, 24 and 60 month progression free survival (PFS) in pediatric NF1 patients with progressive LGG treated with poly-ICLC. 2. Evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive LGG as measured by best objective tumor response rate (CR+PR) within 24 cycles of therapy. 3. Evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive LGG as measured by clinical benefit response rate (CR+PR+MR+SD) after 12 and 24 cycles of therapy. 4. Assess the toxicity associated with poly-ICLC treatment in pediatric NF1 patients with LGG. Exploratory objectives are to: 1. Evaluate the visual outcome measures in children with progressive optic pathway gliomas treated with poly-ICLC. Visual response is defined as 0.2 logMAR or greater in acuity improvement. 2. Evaluate patient reported outcomes and quality of life measures. 3. Evaluate biological correlates. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04734444 -
SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue
|
N/A | |
Recruiting |
NCT01837862 -
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT06104488 -
A Study of Avutometinib for People With Solid Tumor Cancers
|
Phase 1 | |
Completed |
NCT04659421 -
Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas
|
Phase 2 | |
Recruiting |
NCT04174820 -
Child's Study of the Impact of PF Lesion on Motor Skills, Language, Cognitive Functioning and Social Cognition
|
||
Completed |
NCT02197637 -
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
|
Phase 2 | |
Completed |
NCT05373394 -
Evaluation of Cognitive and Motor Neurological Disorders in the Short and Long Term After Surgery for the Removal of a Diffuse Low-grade Glioma of the Supplementary Motor Area
|
||
Recruiting |
NCT05406700 -
Niraparib In Recurrent IDH 1/2 Gliomas
|
Early Phase 1 | |
Active, not recruiting |
NCT04865315 -
A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors
|
||
Recruiting |
NCT06159478 -
Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)
|
Phase 2 | |
Recruiting |
NCT06381570 -
Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas
|
Early Phase 1 | |
Terminated |
NCT03763422 -
Trial in Low Grade Glioma Patients: Wait or Treat
|
Phase 3 | |
Completed |
NCT04346472 -
Longitudinal MRI Assessment in Patients With Diffuse Low-grade Gliomas
|
||
Active, not recruiting |
NCT03948490 -
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
|
N/A | |
Recruiting |
NCT04923126 -
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
|
Phase 1/Phase 2 | |
Completed |
NCT00782626 -
Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
|
Phase 2 | |
Completed |
NCT05873946 -
Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery
|
||
Not yet recruiting |
NCT05555550 -
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
|
Early Phase 1 | |
Withdrawn |
NCT05233215 -
GROW (Glioma Specialists Reaching Out With Support) Support
|
N/A | |
Completed |
NCT01497860 -
Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
|
Phase 2 |